Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alain H Rook

Showing results (91-100 of 98) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 98 results.
Cancer|April 29, 2014
Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) projectKenneth R Carson, Scott D Newsome, Ellen J Kim, et al.
JAMA Dermatology|October 28, 2020
Low-Dose Total Skin Electron Beam Therapy as Part of a Multimodality Regimen for Treatment of Sézary Syndrome: Clinical, Immunologic, and Molecular AnalysisJoseph S Durgin, Neha N Jariwala, Maria Wysocka, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 28, 2017
Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomasJoan Guitart, M Estela Martinez-Escala, Antonio Subtil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2019
Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II StudyMichael S Khodadoust, Alain H Rook, Pierluigi Porcu, et al.
The Lancet. Oncology|August 14, 2018
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trialYoun H Kim, Martine Bagot, Lauren Pinter-Brown, et al.
JAMA Dermatology|July 20, 2022
Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical TrialEllen J Kim, Aaron R Mangold, Jennifer A DeSimone, et al.
Blood|January 6, 2026
Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapiesAlberto Carturan, Mathew G Angelos, Puneeth Guruprasad, et al.
Science Immunology|July 19, 2024
CD5 deletion enhances the antitumor activity of adoptive T cell therapiesRuchi P Patel, Guido Ghilardi, Yunlin Zhang, et al.
Pageof 10

Showing results (91-100 of 98) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 98 results.
Cancer|April 29, 2014
Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) projectKenneth R Carson, Scott D Newsome, Ellen J Kim, et al.
JAMA Dermatology|October 28, 2020
Low-Dose Total Skin Electron Beam Therapy as Part of a Multimodality Regimen for Treatment of Sézary Syndrome: Clinical, Immunologic, and Molecular AnalysisJoseph S Durgin, Neha N Jariwala, Maria Wysocka, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 28, 2017
Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomasJoan Guitart, M Estela Martinez-Escala, Antonio Subtil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2019
Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II StudyMichael S Khodadoust, Alain H Rook, Pierluigi Porcu, et al.
The Lancet. Oncology|August 14, 2018
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trialYoun H Kim, Martine Bagot, Lauren Pinter-Brown, et al.
JAMA Dermatology|July 20, 2022
Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical TrialEllen J Kim, Aaron R Mangold, Jennifer A DeSimone, et al.
Blood|January 6, 2026
Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapiesAlberto Carturan, Mathew G Angelos, Puneeth Guruprasad, et al.
Science Immunology|July 19, 2024
CD5 deletion enhances the antitumor activity of adoptive T cell therapiesRuchi P Patel, Guido Ghilardi, Yunlin Zhang, et al.
Pageof 10